

#### Jeffrey Kamlet, MD,

is chief attending physician at the Healing Visions clinic in St. Kitts, and the president of the Florida Society of Addiction Medicine.



Kenneth Alper, MD,

is an Associate Professor of Psychiatry and Neurology at NYU School of Medicine, and organized the 1999 First International Conference on Ibogaine and co-edited (w. Stanley Glick) the Proceedings of that confer-

ence (The Alkaloids Vol. 57, Acad. Press, 2001).



#### **Emmanuel Onaivi**, PhD, Assistant Professor at William Paterson College, M.Sc. in Pharmacology, Ph.D. in Neuropharmacology. He will present on NIDAfunded studies of the

effects of ibogaine on gene expression activated by alcohol and addictive drugs.



#### Howard Lotsof

**Discovered Ibogaine as** an effective drug detox treatment. Holder of patents for ibogaine's use vs.: • Narcotics Stimulants
Nicotine Alcohol • PolyDrug Dependence.

#### What is Ibogaine?

Ibogaine, derived from the African root Tabernanthe iboga, has a novel mechanism of action that is different from other pharmacotherapeutic approaches to addiction. Relevant issues to be addressed by this forum include the distinctive social and ethnographic aspects of the informal ibogaine treatment context, its cost-effectiveness as a treatment option, and the policy implications of ibogaine's status as a Schedule 1 substance.

Ibogaine is currently without formal approval as a treatment option in the U.S. However, a distinctive unofficial treatment network, created by international selfhelp movements in response to the demand of the addicts, has provided ibogaine treatment in non-medical settings such as an apartment or country house.

Participants in this forum/will represent the basic and clinical neurosciences, the disciplines of ethnography and sociology, and the FDA, NIDA and the pharmaceutical industry. The promotion of discussion and exchange of information and views among the participants receives significant emphasis in the forum program and agenda.

Topics to be covered include ibogaine's mechanism of action, safety and efficacy, interaction with memory and neurophysiology, and ethnographic and policy perspectives. The proposed presenters have accumulated significant new data on neurobiological, clinical, and sociocultural aspects of ibogaine.

#### **Advocacy Groups:**

Cures Not Wars 1-212-677-7180 www.cures-not-wars.org cnw@cures-not-wars.org

MindVox http://ibogaine.mindvox.com

Benu Project 1-212-304-0035

Dora Weiner Foundation 1-718-442-2754

Positive Health Project 1-212-465-8304

**Harm Reduction Coalition** 1-212-213-6376

Sponsored in part by:

CURESnotWARS



# Forum February 20–21 (Sunday–Monday)

Alex Grey's Gallery **Chapel of Sacred Mirrors** 

Ibogaine

540 West 27th Street **Fourth Floor** 

**Registration: \$20 per day** 212-677-4899

### Sunday, February 20, 2005; Noon to 7 pm

**12:00 noon–12:45 pm** Registration; Introductory Remarks: Rommell Washington, Benu Project.



12:45 pm-3:15 pm

Ibogaine and the Search for Lost Sacraments. Moderated by Alex Grey, with Dana Beal, author, *The Ibogaine Story*, Carl Ruck, PhD, author,



*The Apples of Apollo,* Paul DeRienzo, former editor-in-chief, *High Times,* Rev. Ron Sala, Unitarian, Rob Gordon, Cures Not Wars. Discussion

3:15 pm–3:45 pm Break

**3:45 pm–5:45 pm** Hands-on Ibogaine Treatment: Tips and Pointers. Howard Lotsof, Patrick Kroupa, Dimitri Mugianis, Adam Nodelman, Chris Laurance, Andrea Plementos.

5:45 pm–7:00 pm Screening of *Ibogaine: Rite of Passage* with Ben De Loenen.



## Monday, February 21, 2005; 10 am to 7 pm



**10:00 am–10:30 am** Registration; Introduction by H.S. Lotsof.


**10:30 am–11:30 am** New Findings: Dopamine, Craving and Ibogaine. Carl Anderson, PhD.

**11:30 am–1:15 pm** Medical Ibogaine Therapy. Jeffrey Kamlet, MD, with Intro by Patrick Kroupa.

1:15 pm–1:45 pm Break

1:45 pm–3:15 pm Scientific Panel: Assessing New Possibilities of Ibogaine. Kenneth R. Alper, MD, Emmanuel Onaivi, PhD, John Freelander. Discussion

#### 3:15 pm-3:45 pm Break



**3:45 pm–5:15 pm** Ibogaine's Anti-viral Effects. Vic Hernandez, PhD, Jason Farrell, Chris Laurance, Richie D. Discussion

**5:15 pm–7:00 pm** Final Wrap-up Panel. Kenneth Alper, MD and principal panelists.

The Monday session will be attended by representatives of various city and state agencies.